Clinical trial
Odronextamab for Relapsed/Refractory Large B-Cell Lymphomas Before Definitive Lymphoma-Directed Therapies
NCT06784726 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Odronextamab for Relapsed/Refractory Large B-Cell Lymphomas Before Definitive Lymphoma-Directed Therapies
- Lead sponsor
- University of Washington
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- September 4, 2025
- Completion date
- April 11, 2033
- Enrollment
- 27 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent diffuse large b-cell lymphoma, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma, recurrent primary mediastinal large b-cell lymphoma, recurrent transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma, refractory primary mediastinal large b-cell lymphoma, refractory transformed indolent b-cell non-hodgkin lymphoma to diffuse large b-cell lymphoma